© 2020 Insiliance - Health & AI Scientific Consortiums and Projects  for CNS Drug (Re)positioning and Treatments Optimization - Paris - France



EFFICIENCY & EFFICACITY. AI can reduce risks and costs, attract serendipity and improve decision making for CNS drug (re)positioning and treatments optimization

Patients suffering from CNS diseases want drugs or more efficient drugs, quickly.


Pharmaceuticals, biotechs, patients associations and foundations for health want a more fertile R&D while at best only 1 out of 14 entering the clinical phase will get an FDA approval (Dowden & Munro - 2019). 


MDs and health centers want a better knowledge of possible response to treatments in order to optimizing prescriptions and care pathways.


Public health authorities and health insurers want to improve resources allocation while CNS diseases represent the first economic and social burden with a third of health expenses.


They are the reasons why the mission of INSILIANCE is to select for its own account and for partners, by the association of AI solutions and BioData/DataScience and Health experts, CNS drugs to be (re)positioned and to be moved towards the clinic with a higher rate of success and a decisive therapeutic potential.

CROSS-CULTURAL & EXPERTISE. Validating health data, algorithms design and results enable BioData Science + Health researchers and executive's collaboration   


Because medicine is an art, we have the conviction that experience, expertise, intuition, sense of others, transparency, confidentiality and ethics are crucial for the effectiveness and the efficiency of AI for CNS Drug (Re)positioning & Treatments Optimization consortiums and projects.


AI is a great and high-potential technology for Drug (Re)positioning & Treatments Optimization only if researchers and executives trust knowledge they get.

All the more so with the multiplication of sources and the explosion of volumes of health data we get consolidated information of with respect to rules, regulations and patients privacy. And with everyone's whish to avoid any "black box" effect throughout the process.

Therefore, INSILIANCE always associates MDs, pharmacists and biologists with computer and BioData scientists and, whenever needed, business developers, economists, regulators, ethical referents and executives.

PARTNERSHIPS & KEY KNOWLEDGE. Together, we can share the mind of Champollion applied to Health Data in order to achieve our missions for patients


Like hieroglyphs, scientific literature, patent, "omics" and real-world data can better deliver their full potential of meaning and semantic key knowledge.


For improving the recognition of your experts, your data - possibly your own AI solutions -, your institution, the odds percentage of your projects, your decision-making processes and your economic model:

     1. soon you may take benefit from our selection of CNS drugs to be (re)positioned and to be moved towards the clinic with a high therapeutic potential

     2. You can join our CHAMPOLLION.AI.PLATFORM consortium as a "Pioneer Partner"

     3. you can use our off-the-shelf INSILIANCE HEALTH KEY KNOWLEDGE AI solutions delivered with internal and partners' researchers & executives

     4. we can pool our expertise in Health & AI Scientific Consortiums & Projects engineering and funding

In a dynamic of an Health & AI scientific consortium or bilateral project approaches, INSILIANCE can imagine a fair agreement with you.